165 related articles for article (PubMed ID: 11587375)
1. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
2. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr.
Mondello P; Cuzzocrea S; Navarra M; Mian M
Oncotarget; 2016 Feb; 7(7):7597-609. PubMed ID: 26657116
[TBL] [Abstract][Full Text] [Related]
3. The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.
Evens AM; Spies WG; Helenowski IB; Patton D; Spies S; Jovanovic BD; Miyata S; Hamilton E; Variakojis D; Chen J; Naumovski L; Rosen ST; Winter JN; Miller RA; Gordon LI
Clin Cancer Res; 2009 Oct; 15(20):6462-71. PubMed ID: 19825958
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.
Dillman RO
Clin Exp Med; 2006 Mar; 6(1):1-12. PubMed ID: 16550338
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Durando M; Gopal AK; Tuscano J; Persky D
Oncologist; 2024 Apr; 29(4):278-288. PubMed ID: 38207010
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.
Puvvada SD; Guillén-Rodríguez JM; Yan J; Inclán L; Heard K; Rivera XI; Anwer F; Mahadevan D; Schatz JH; Persky DO
Oncology; 2018; 94(5):274-280. PubMed ID: 29471300
[TBL] [Abstract][Full Text] [Related]
7. The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.
Laoruangroj C; Atherton PJ; Wiseman GA; Ansell S; Feldman AL; Schumacher P; Witzig TE
Leuk Lymphoma; 2024 Mar; 65(3):333-338. PubMed ID: 38189774
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
9. Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma.
Lehnert M; Ludwig H; Zojer N
Onco Targets Ther; 2009 Feb; 2():199-208. PubMed ID: 20616907
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-Up of
Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
[TBL] [Abstract][Full Text] [Related]
11. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
[TBL] [Abstract][Full Text] [Related]
12. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
[TBL] [Abstract][Full Text] [Related]
13. Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.
Sánchez Ruiz AC; de la Cruz-Merino L; Provencio Pulla M
Ther Adv Hematol; 2014 Jun; 5(3):78-90. PubMed ID: 24883180
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy of solid tumors: searching for the right target.
Song H; Sgouros G
Curr Drug Deliv; 2011 Jan; 8(1):26-44. PubMed ID: 21034423
[TBL] [Abstract][Full Text] [Related]
16. Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
Press OW
J Clin Oncol; 2008 Nov; 26(32):5147-50. PubMed ID: 18854559
[No Abstract] [Full Text] [Related]
17. Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma.
Calais PJ; Turner JH
World J Nucl Med; 2012 Sep; 11(3):110-6. PubMed ID: 23372448
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Radiolabeling of a [
Winter G; Hamp-Goldstein C; Fischer G; Kletting P; Glatting G; Solbach C; Herrmann H; Sala E; Feuring M; Döhner H; Beer AJ; Bunjes D; Prasad V
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
